drugset
drugset / Trial / NCT02449252

Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma

NCT02449252 ↗

Phase 3 Unknown 120 enrolled Wuhan University
RandomizedParallel-groupOpen-labelTreatment

Summary

Radiotherapy (RT) is an important option for patients with limited stage FL. The recommended approach for patients with limited stage FL by The National Comprehensive Cancer Network (NCCN) is 24Gy\~30Gy consolidation RT following effective systemic therapy. There is no universal consensus for a ''standard'' RT field size in the treatment of limited stage FL. The involved-site radiotherapy (ISRT) has been treated effectively for these patients. However, the certain target volumes of ISRT need to be defined for patients with limited stage FL after effective chemotherapy.

Timeline

Start
2015-10
Primary completion
2019-10
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified 750 mg/m2 —
Background Doxorubicin Other / unclassified 50 mg/m2 —
Background Prednisone Other / unclassified 60 mg/m2 —
Background Vincristine Small molecule 1.4 mg/m2 —

Indications

follicular lymphoma